Anat Cohen-Dayag, Ph.D.
President and CEO
Dr. Cohen-Dayag joined Compugen in 2002 and held various positions. In November 2008, Dr. Cohen-Dayag was appointed as Vice President, Research and Development. In June 2009, Dr. Cohen-Dayag was appointed as co-Chief Executive Officer of Compugen and in March 2010, Dr. Cohen-Dayag was appointed as Compugen’s President and CEO. Dr. Cohen-Dayag joined Compugen’s Board of Directors in 2014. Prior to joining Compugen, Dr. Cohen-Dayag was head of research and development and member of the Executive Management at Mindsense Biosystems Ltd. Prior to Mindsense Biosystems Ltd., Dr. Cohen-Dayag served as a scientist at the R&D department of Orgenics Ltd. Dr. Cohen-Dayag holds a B.Sc. in Biology from the Ben-Gurion University, Israel, and an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science, Israel. Additionally, Dr. Cohen-Dayag is a director of Ramot at Tel-Aviv University Ltd., and a director of the IATI (Israeli Advanced Technologies Industries).
Chief Financial and Operating Officer
Mr. Krashin joined Compugen in 2014 as Chief Financial Officer of Compugen. In 2016, he was appointed also Chief Operating Officer. Mr. Krashin has over 15 years of experience in capital markets, finance and business development. He served as a chief financial officer for both public and private companies, the most recent being AnyClip Media and Spacenet Inc. Mr. Krashin was also the CFO of Gilat Satellite Networks where he led the company's global finance and related operations, including business development, M&A activities, investor relations and administration. Mr. Krashin is a certified public accountant and began his professional career with Kesselman and Kesselman, PWC, Israel. Mr. Krashin holds a B.A. in Business Administration and Accounting from the College of Management, Rishon Le’Zion.
Henry Adewoye, MD
Chief Medical Officer
Dr. Adewoye joined Compugen in March 2018 as Chief Medical Officer, bringing to Compugen over 20 years of extensive experience in leading multiple clinical trials in Oncology and Hematology in both the biopharmaceutical industry and academia. Before Compugen, Dr. Adewoye was with Gilead Sciences Inc., as Clinical Director in Oncology Clinical Research and was on the Oncology Leadership Team. He most recently served as Project Team and Clinical Lead for Idelalisib (first-in-class PI3K delta inhibitor approved for the treatment of relapsed CLL, FL/SLL) and Andecaliximab (MMP9 mAb inhibitor). Previously, he was Clinical Research Medical Director in Oncology at Amgen Inc. Dr. Adewoye was the Global Medical Monitor for the initial registrational trial of the bispecific antibody blinatumomab (Blincyto®) and several Phase 2 and 3 studies evaluating VEGF inhibitors (Motesanib, Trebananib) in patients with solid tumors. Dr. Adewoye completed his Fellowship in Hematology/Oncology at Boston Medical Center and completed his residency in Internal Medicine at Meharry Medical College. Dr. Adewoye received his medical degree at the University of Jos, Nigeria and Fellowship training in Hematology and Laboratory medicine at the University College Hospital Ibadan, Nigeria. Dr. Adewoye is Board Certified by the American Board of Internal Medicine in Medical Oncology, Hematology and Internal Medicine.
John Hunter, Ph.D.
Chief Scientific Officer
Dr. Hunter joined Compugen in April 2012 as Vice President, Antibody R&D and Site Head, Compugen USA, Inc., and was appointed Chief Scientific Officer in April 2018 with overall responsibility for Compugen’s research and development activities. Dr. Hunter brings to Compugen over 20 years of scientific expertise in mAb research, oncology drug development, and translational medicine. Dr. Hunter continues to serve as the Site Head of Compugen USA, Inc., Compugen’s subsidiary drug development site in South San Francisco, CA. Prior to joining Compugen, Dr. Hunter served as a Senior Director at XOMA, managing strategic and functional activities related to building a robust preclinical mAb pipeline. He began his industry career at Millennium Pharmaceuticals, where he specialized in oncology therapeutics research. Dr. Hunter holds a B.A. in Biology from Hartwick College and a Ph.D. in Immunology from the University of California San Francisco.
Zurit Levine, Ph.D.
Senior Vice President, Technology Innovation
Dr. Levine was appointed Senior Vice President, Technology Innovation in October 2018, responsible for leading and advancing the Company’s computational innovation towards new discovery fields and areas. In this capacity Dr. Levine is also responsible for Compugen’s IP strategy and portfolio. Dr. Levine joined Compugen in 1999 and has held several positions in Compugen’s Research & Development department. In 2004, she was appointed Director of Therapeutic Selection & Validation, which position she held until 2007 when she was appointed Director of Therapeutic Discovery. In 2009, she was appointed Executive Director of Research & Development. From January 2010 to August 2011, she held the position of Vice President, Research and Development. In August 2011 she was appointed Vice President, Research and Discovery. Dr. Levine holds a B.Sc. in Biology, a M.Sc. in Biochemistry and a Ph.D. in Biochemistry, all from the Tel Aviv University, Israel.
Riki Schwartz, Ph.D.
Vice President, Research and Discovery
Dr. Schwartz joined Compugen in October 2018 as Vice President – Research and Discovery, responsible for the Company’s computational discovery and research & validation groups. Dr. Schwartz has over 15 years of leadership experience in the pharmaceutical industry. Prior to joining Compugen, she served as CEO of BARcure LTD. an early-stage drug development company and as a drug development advisor to startup companies. Prior to that, Dr. Schwartz spent 13 years at Teva Pharmaceutical Industries serving in various management positions, with an overall responsibility for drug development programs ranging from the concept stage and up to Phase III and registration and leading multidisciplinary global teams across different professional areas (including clinical, pharmacology, regulatory affairs, non-clinical safety and CMC). Dr. Schwartz holds a B.Sc. in Biology from Tel Aviv University and an M.Sc. and Ph.D. in Immunology from the Sackler Faculty of Medicine, Tel-Aviv University.
Vice President, Human Resources
Dorit Amitay joined Compugen’s human resources department in 1999, bringing with her over ten years of experience. During her tenure at the Company, Ms. Amitay took on increasingly larger roles in the HR department until assuming her current position in 2007. Prior to joining Compugen, Ms. Amitay worked for one of the leading Israeli recruitment and placement agencies. Ms. Amitay holds a B.A. in Social Sciences and an MBA, both from Ben Gurion University in Israel and an M.A. in Organizational Consulting and Development from The College of Management Academic Studies.